The purpose of the Keynote lung cancer clinical trials is to see if the investigational drug, pembrolizumab, will slow down or stop the growth of lung cancer cells.
Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.
Lung cancer occurs when cells inside the lung grow abnormally. As more cells grow, they start to form a tumor and may spread to other areas in the body. Non-small cell lung cancer is the most common type of lung cancer. Its sub-types include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
Depending on the stage of your cancer and other factors, treatment options for people with non-small cell lung cancer may include surgery, radiotherapy, chemotherapy or palliative care. Taking part in a clinical trial may also be an option for certain patients.
Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
You can also call our clinical trial information center at 1-888-577-8839 to learn more.
|Trial Description||Keynote Trial||Condition||Phase and Status|
|Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer||189||Non-Small-Cell Lung Carcinoma||Phase 3 Active, not recruiting|
|A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer||407||Non-small Cell Lung Cancer||Phase 3 Recruiting|
|Study of Pembrolizumab in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma||001||Cancer, Solid Tumor||Phase 1 Active, not recruiting|
|Study of Two Doses of Pembrolizumab Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer||010||Non Small Cell Lung Cancer (NSCLC)||Phase 2/Phase 3 Active, not recruiting|
|Study of Pembrolizumab Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer||011||
||Phase 1 Recruiting|
|Study of Pembrolizumab in Participants With Advanced Non-small Cell Lung Cancer||025||Non-small Cell Lung Cancer||Phase 1 Active, not recruiting|
|A Study of Pembrolizumab in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer||021||Non-small Cell Lung Carcinoma||Phase 1/Phase 2 Active, not recruiting|
|Study of Pembrolizumab Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer||024||Non-Small Cell Lung Carcinoma||Phase 3 Active, not recruiting|
|Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab in Chinese Participants With Non-Small-Cell Lung Cancer||032||Non-Small-Cell Lung Cancer||Phase 1 Active, not recruiting|
|Study of MK-3475 Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer||042||Non-small Cell Lung Cancer||Phase 3 Active, not recruiting|
|Study of Pembrolizumab vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy||091||Non-small Cell Lung Cancer||Phase 3 Recruiting|
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.